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Background: Although symptoms of infection caused by cytomegalovirus (CMV) in healthy adults are
generally mild, the virus is known to produce severe symptoms most often in immunocompromised patients.
Patients with chronic renal failure are prone to CMV infection. CMV, as a nosocomial infection in
immunocompromised patients, is a problem for clinicians.
Aim: We aimed to investigate the seroprevalence of CMV infection among the haemodialysis (HD) patients in
our region.
Patients and Methods: Serum samples were taken from 255 patients who received treatment in 3 different
HD clinics and a control group of 70 healthy persons. Enzyme-linked immunosorbent assay (ELISA) was used
to investigate anti-CMV IgG and IgM antibodies.
Results: Positivity for anti-CMV IgG was found in 254 (99.6%) of the 255 HD patients and 58 (82.9%) of
the 70 controls. The difference between the 2 groups was statistically significant (P < 0.05). Positivity for
anti-CMV IgM antibody was noted in 1 (0.4%) of the 255 HD patients.
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Conclusions: The prevalence of CMV infection among HD patients in our region was quite high. Because
patients receiving HD treatment can be exposed to CMV infection, we recommend that HD patients who are
susceptible to CMV infection should be identified with anti-CMV IgG and IgM specific serological tests.
Key Words: Haemodialysis, CMV, seroprevalence

Hemodiyaliz Hastalar›nda Sitomegalovirus Antikor Seroprevalans›
Giriﬂ: Sa¤l›kl› yetiﬂkinlerde CMV’nin neden oldu¤u enfeksiyonlar genellikle ›l›ml› olmas›na ra¤men, bu
enfeksiyonlar immun zorluklularda ço¤unlukla ciddi semptomlar oluﬂturmaktad›r. Kronik böbrek hastal›¤› olan
hastalar CMV enfeksiyonuna yatk›nd›r. ‹mmun zorluklu hastalarda CMV nozokomiyal enfeksiyonlar›
klinisyenler için önemli bir problemdir.
Hastalar ve Yöntem: Üç hemodiyaliz merkezinde tedavi edilen 255 hastadan ve kontrol grubu için 70 sa¤l›kl›
kiﬂiden serum örnekleri al›nd›. Anti-CMV IgG ve IgM antikorlar›n› araﬂt›rmak için enzim ba¤l› immunosorbent
testi kullan›ld›.
Bulgular: Toplam 255 hemodiyaliz hastas›n›n 254 (% 99.6)’ünde ve kontrol grubundaki 70 kiﬂinin 58
(%82.9)’inde anti-CMV IgG pozitivitesi tespit edildi. ‹ki grup aras›ndaki fark istatiksel olarak anlaml› bulundu
(P<0.05). Hemodiyalizdeki 255 hastan›n 1 (% 0.4)’inde anti-CMV IgM antikor pozitivitesi tespit edildi.
Sonuç: Sonuç olarak, bölgemizdeki hemodiyaliz hastalar› aras›nda CMV prevalans› oldukça yüksek
bulunmuﬂtur. Hemodiyaliz tedavisi alan hastalar CMV enfeksiyonuna maruz kalabilece¤inden, CMV
enfeksiyonuna duyarl› hemodiyaliz hastalar›n›n anti-CMV IgG ve IgM spesifik serolojik testleriyle taranmas›n›
önermekteyiz.
Anahtar Sözcükler: Hemodiyaliz, CMV, seroprevalans
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Cytomegalovirus (CMV) is found throughout the world among all socio-economic
groups and infects between 50% and 85% of adults by the age of 40 years. CMV
infection is more widespread in developing countries and in areas of low socio-economic
conditions. Once a person becomes infected, the virus remains alive, but usually
dormant, within that person's body for the duration of their lifespan. It rarely causes
recurrent disease unless the person's immune system becomes suppressed due to
therapeutic drugs or disease. Therefore, for the vast majority of people, CMV infection
is not a serious problem (1,2).
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It has been well studied and documented that uraemic
patients, as well as patients on haemodialysis (HD), have
impaired immune responses, which result in higher
prevalence rates of morbidity and mortality as a result of
viral bacterial, or parasitic infections, or from malignant
maladies (3,4).
With regard to viral infections, in chronic patients on
HD, the association of both hepatitis B and hepatitis C
virus has been extensively investigated worldwide.
Investigations concerning commonly encountered viral
infections in HD patients have been quite limited, except
for studies of CMV (5).
CMV infection can occur at any time during the
lifespan of humans; it can even be acquired in utero. The
incidence of seropositivity increases with age. Among HD
patients, 60%-90% are seropositive, depending on age
and socio-economic circumstance (6).
While initial CMV infection can cause serious disease in
immunocompromised patients, a more common problem
is reactivation of the dormant virus. Infections caused by
CMV are a major cause of disease and death in
immunocompromised patients, which include organ
transplant recipients, patients undergoing HD, cancer
patients, patients receiving immunosuppressive drugs,
and HIV-infected patients (5,6).
The aim of this study was to investigate the
seroprevalence of anti-CMV IgG and IgM in patients on
HD in 3 different HD clinics in our region.

Materials and Methods
This study was carried out in Antakya, Turkey,
between March 2004 and June 2004 and included 255
HD patients between the ages of 14 and 91 years who
were selected from 3 Antakya area HD clinics
(Haemodialysis Centre of Antakya State Hospital, Antakya
Haemodialysis Centre, Emir Haemodialysis Centre). The
control group included 70 healthy volunteers who were
between 12 and 65 years old.
To determine the seroprevalence of CMV infections,
blood samples were collected from the 255 HD patients
and the 70 healthy persons for antibody testing, and
centrifuged at 1500 rpm for 5 min to obtain serum
samples, which were then stored at -20 °C until tested.
The length of the time on HD and the weekly number of
HD treatments of each HD patient was recorded.
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Enzyme-linked immunosorbent assay (ELISA) (Abbott
kits, Abbott Laboratories, USA) was used to test for the
presence of anti-CMV IgG and IgM antibodies according
to the manufacturer’s instructions.
Statistical analysis
The statistical analysis was performed using chisquare test and Statistical Package for the Social Sciences
(SPSS) software. P values less than 0.05 were considered
statistically significant.
Results
The mean age of the 255 HD patients was 53.94 ±
17.3 years (mean ± SD). The gender distribution of the
patients was 175 (68.6%) males and 80 (31.4%)
females. The mean age of the healthy control group was
47.21 ± 18.6 years (mean ± SD) and included 33
(47.1%) males and 37 (52.9%) females. Positivity for
anti-CMV IgG was determined in 254 (99.6%) of the
255 HD patients and 58 (82.9%) of the 70 controls. The
difference between the 2 groups was statistically
significant (P < 0.05) (Figure 1).
Although all of the subjects in the control group were
seronegative for anti-CMV IgM, 1 (0.4%) of the HD
patients was seropositive for anti-CMV IgM. The
difference between the 2 groups was not statistically
significant (P > 0.05).
The length of the time on HD was 35.1 ± 32.7
months (mean ± SD) in patients with anti-CMV IgG
seropositivity. A significant correlation was not found
between the length of the time on HD and anti-CMV IgG
seropositivity (P > 0.05).
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Figure 1. The ratio of CMV IgG antibodies in haemodialysis patients
compared to healthy control group.
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Discussion
CMV is the prototype member of the
Betaherpesvirinae. As with all members of the
Herpesviridae, CMV has the ability to persist in the host
in a dormant state following primary infection. More than
80% of healthy adults are seropositive, indicating
previous exposure (7). CMV infections are ubiquitous
throughout the world, infecting between 40% and 100%
of the entire human population (2,3).
Seroprevalence rates of CMV vary geographically. de
Ory Manchon et al. (8) found that seroprevalence for
anti-CMV IgG in the general population in Madrid was
62.8%, ranging from 58.4% in men to 66.7% in women
(8). In another study, carried out in Tunisia, anti-CMV IgG
antibodies were detected in 98.57% of women and
95.71% of men (9). Studies of pregnant women in
France and Saudi Arabia reported CMV seroprevalences
of 51.5% and 92.1%, respectively (10,11). In a study of
the general population in Turkey, an 87.5%
seropositivity rate for anti-CMV IgG was found (12),
which is similar to the 82.9% rate of the present study’s
control group, but lower than the rate in our HD patients
(99.6%).
Infectious disease is the most serious complication in
immunosuppressed patients and is the major cause of
death in renal transplant recipients. Bacterial, fungal, and
protozoan infections, and viruses of the human herpes
group (herpes simplex virus, varicella-zoster virus,
Epstein-Barr virus, and CMV) are known to be of major
importance. The most common and clinically relevant
virus of this group is CMV (13). While CMV infection
proceeds asymptotically in the majority of
immunocompetent persons, it can lead to serious
complications in immunosuppressed patients (2,3).
It is well known that patients on regular HD
treatment are in an immunodeficient state (14). Patients
on HD suffer from general immune incompetence,
resulting in a high incidence of infectious complications.
Various abnormalities in T cell function of HD patients
have been described (15). It has been suggested that
changes in immune response to infectious agents in
patients on HD might be due to impaired monocyte
function; uraemic and HD patients overproduce
proinflammatory cytokines, such as interleukin-1 beta,
tumour necrosis factor-alpha, and interleukin-6 (16).
Yalinay et al. (17) investigated the presence of CMV in
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immunosuppressive patients and positivity for CMV-DNA
was 31.7% in HD patients (17). The rate of positivity for
anti-CMV IgM was 13.7% (116/846) in a kidney
transplantation series by Moray et al. (18). In the present
study, none of the 70 healthy controls tested positive for
anti-CMV IgM antibody, but 1 HD patient (0.4%; 1/255)
was positive for anti-CMV IgM. These data suggest that
patients
with
chronic
renal
failure
and
immunosuppression are at risk for CMV infection. In the
immunocompetent individual, the virus and host exist in a
symbiotic equilibrium and disease manifestations are
rarely encountered. However, when the host immune
system is compromised, the virus is able to exert its full
pathogenic potential (19,20). Bacterial and viral
infections represent the most frequent complications in
patients with chronic renal failure, due to changes in
immunological status (21).
Very few studies have been conducted to determine
seroprevalence of CMV infection in HD patients in Turkey.
In the present study, while the rate of anti-CMV IgG
seropositivity in HD patients was 99.6%, this rate was
82.9% in the control group. The difference between the
2 groups was statistically significant (P < 0.05), which
may have been due to transmission of CMV during the HD
procedure.
With regard to studies from other countries on the
seroprevalence of anti-CMV antibodies in HD patients,
Konstantopoulou et al. (22) investigated the distribution
of anti-CMV IgG and IgM in 173 HD patients. While
positivity for anti-CMV IgG was found in 85 (85%) of
100 healthy controls, 161 (93%) of the 173 HD patients
were seropositive for anti-CMV IgG antibodies (22). In a
study conducted by Korcakova et al. (23) positivity for
anti-CMV IgG was found in 80% of HD patients and in
62% of healthy blood donors, whereas positivity for antiCMV IgM was found in only one of the 30 dialysed
patients. Compared to healthy blood donors, a higher
percentage of CD 8 lymphocytes and natural killer activity
was impaired in all chronic patients in the HD programme
(23). The results of this study were similar to our results,
though the reported seropositivity for anti-CMV IgG
among HD patients was lower than the 99.6% found in
the present study.
In a study of infectious complications in 453 renal
transplant recipients, CMV infection was the most
frequent opportunistic pathogen occurring in renal
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transplants (24). The data support that patients with
chronic renal failure have a risk of CMV infection. As a
result, although CMV is not an important micro-organism
in immunocompetent persons, it is a serious pathogen in
immunosuppressed people, like HD patients.
Abbas et al. (25) reported that anti-CMV antibodies in
patients with chronic renal failure undergoing HD were
correlated to the number of the dialysis sessions (20). In
the current study, a significant correlation was not found
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between the length of the time on HD treatment and antiCMV IgG positivity (P > 0.05).
In conclusion, the results of the present study confirm
a high prevalence of CMV infection among HD patients in
the Antakya region. Patients on HD can be exposed to
CMV infection. For this reason, we recommend that HD
patients who are susceptible to CMV infection be
identified by anti-CMV IgG- and IgM-specific serological
tests.
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